Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 4/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3284382 | 0.98 | TP53 (0.43) | LMNAPOLBTP53ALDH1A1HPGD | |
| SCHEMBL3287484 | 0.94 | LMNA (0.43) | LMNAPOLBTP53ALDH1A1HPGD | |
| SCHEMBL3286661 | 0.93 | LMNA (0.45) | LMNAPOLBTP53ALDH1A1HPGD | |
| SCHEMBL3285295 | 0.92 | TP53 (0.42) | LMNAPOLBTP53ALDH1A1HPGD | |
| SCHEMBL3292038 | 0.91 | LMNA (0.45) | LMNAPOLBTP53ALDH1A1HPGD | |
| SCHEMBL13376525 | 0.91 | LMNA (0.44) | LMNAPOLBTP53ENPP2 | |
| SCHEMBL3288361 | 0.91 | TP53 (0.44) | LMNAPOLBTP53ALDH1A1HPGD | |
| SCHEMBL3285307 | 0.91 | TP53 (0.44) | LMNAPOLBTP53ALDH1A1HPGD | |
| SCHEMBL3285304 | 0.91 | TP53 (0.44) | LMNAPOLBTP53ALDH1A1HPGD | |
| SCHEMBL3292902 | 0.90 | LMNA (0.42) | LMNAPOLBTP53ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
| WO-2006089909-A1 | NOVEL ANTITHROMBOTIC SUBSTITUTED PYRROLIDINONES, THE PRODUCTION AND USE THEREOF IN THE FORM OF MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | PYCR1, S100A9, REV1 | LMNA 1767/4885POLB 124/4885TP53 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.